Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 GeneticVariation group BEFREE In addition to LCs described above, some carcinomas demonstrated low-abundance MET exon 14Δ-specific signal. 31472177 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression group BEFREE The present work seeks to assess whether pancreatic carcinomas release exosomes which express c-Met (proto-oncogene mesenchymal-epithelial transition factor) and PD-L1 (programmed cell death 1 ligand 1), and whether the detection of such expression in serum has diagnostic or prognostic meaning for the affected patients. 31284422 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker group BEFREE C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas. 30909397 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker group BEFREE MET and PD-L1 (SP142) immunohistochemistry was performed in 73 gastric carcinomas with MSI-H. 30455128 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression group BEFREE Normal breast tissues were negative for the L1-MET expression, whereas the triple-negative breast cancer (TNBC) and the high-grade carcinomas were enriched with the L1-MET mRNA (p = 0.005 and p = 0.018, respectively). 30144023 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker group BEFREE Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas. 30032818 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression group BEFREE c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. 30149144 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker group BEFREE This is the first report to analyze the statuses of the MET gene in ECCs, and the two mixed cases exhibited amplifications that are shared with ovarian clear-cell carcinomas. 29633423 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 GeneticVariation group BEFREE CUP adenocarcinomas and poorly differentiated carcinomas harboured the highest frequency of variants in genes involved in signal transduction pathways (e.g.MET, EGFR, HRAS, KRAS, and BRAF). 29973234 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker group BEFREE The EMT and MET have recently been shown to play a key role in the pathogenic processes of sarcomas, which are completely different from those of carcinomas. 28829837 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 GeneticVariation group BEFREE MET mutations were detected in 8.8% (9/102) of triple-negative adenocarcinomas and 20% (9/45) of pleomorphic carcinomas of the lung. 28285687 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker group BEFREE Elevated protein levels in absence of gene amplification were not attributed to mutations, based on results of targeted next-generation sequencing.Our data reveal that clear-cell RCC with MET upregulation show an aggressive behavior and MET copy number increase is evident in a substantial percentage of patients with high-grade carcinomas and metastatic disease. 27894094 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker group BEFREE Amino acid uptake inhibitor studies were performed in four human carcinoma cells (epidermal carcinoma A431, colorectal carcinoma LS180, and lung carcinomas PC14/GL and H441/GL) using the radioisotope analogs [<sup>3</sup>H]MET and [<sup>14</sup>C]MeAIB. 28284101 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression group BEFREE While the prevalence of c-MET mutations and amplifications ranges 0-25%, c-MET upregulation can be found in the majority of squamous head & neck carcinomas. 28259294 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression group BEFREE In vivo experiments were performed to test the effects of c-MET inhibitor on tumor growth in orthotopic mouse xenografts of OCCC cell line RMG1 and a patient-derived tumor xenograft (PDX) model of OCCC. c-MET expression was significantly greater in OCCCs compared with serous carcinomas and normal ovarian tissues (p < 0.001). 27917934 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression group BEFREE Various solid tumors including lung or gastric carcinomas display aberrant activation of the Met receptor which correlates with aggressive phenotypes and poor prognosis. 26238631 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker group BEFREE MET gene amplification correlates with a poor prognosis and poor survival in gastric carcinomas. 25820598 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker group BEFREE MET immunostaining was seen in normal urothelium and was recorded in 459 of 560 analyzable urothelial carcinomas (82.0%). 24853099 2014
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker group BEFREE Moreover, aberrations of MET are associated with EGFR and PTEN signalling and might possess relevance for targeted therapies of salivary gland carcinomas in the future. 23242174 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression group BEFREE MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. 23807774 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression group BEFREE c-MET/phospho-MET expression and MET BISH positivity were observed in 22.2%, 5.6%, and 10.9% of NSCLCs, respectively; they were more prevalent in ADCs (27.3%, 6.9%, and 11.5%, respectively) and sarcomatoid carcinomas (20.9%, 9.3%, and 36.6%, respectively) than in SCCs and large cell carcinomas. 22198430 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker group BEFREE In conclusion, our data suggest that mutation alone plays a minor role in causing aberrancies of the HGF/MET pathway in medulloblastoma in comparison with other malignancies such as breast, hepatocellular, renal, and lung carcinomas. 22447520 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression group BEFREE In 4 (31%) of the 13 cases enrolled, intratumoral heterogeneity for MET gain was documented in invasive carcinoma components, wherein all the relatively differentiated carcinoma components showed low-level gain of MET and all the corresponding poorly differentiated carcinomas showed high-level gain. 21983935 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker group BEFREE If confirmed in patients, this information might prove useful to monitor clinical response to Met-targeted therapies in MET-amplified gastric carcinomas. 21500189 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression group BEFREE MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. 22644302 2012